<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2009</study_start_year><condition>Metastatic Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Metastatic Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Observational</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2103436</full_dataset_link><location>Saudi Arabia</location><study_start_month>1</study_start_month><keyword>Irinotecan</keyword><keyword>Oxaliplatin</keyword><keyword>Capecitabine</keyword><keyword>Bevacizumab</keyword><repository>ECRIN MDR</repository><study_status>Not provided</study_status></additional><is_claimable>false</is_claimable><name>A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer</name><description>A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer</description><dates><creation>2009-01-15</creation></dates><accession>2103436</accession><cross_references><ClinicalTrials___gov>NCT01311050</ClinicalTrials___gov></cross_references></HashMap>